EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$8.21
-0.12 (-1.44%)
▼
5d:
-10.08%
30d:
-5.2%
90d:
-24.33%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Apr 30, 2026
0d
Smart Money Accumulation
EBS is down 10.1% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 721 OI. Call ratio: 93% View Scanner →
Strength: 9.3/10
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called EBS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EBS is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EBS is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.10
Based on -0.1% avg growth
INTRINSIC VALUE TODAY
$8.75
6.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $8.21, which is considered slightly low relative to its 30-day fair value range of $8.04 to $8.84. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.0) compared to its historical average (15.6). Remarkably, the market is currently pricing in an annual earnings decline of 16.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $7.53, while resistance sits at $9.66.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+46.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $7.53, while resistance sits at $9.66.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+46.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$8.04 -
$8.84
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.2% below Wall St target ($12.00)
- WARNING: Recommendation downgraded due to -10.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.04 -
$8.84
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.80
(9.7%)
Support & Resistance Levels
Support Level
$7.53
Resistance Level
$9.66
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.02
Wall Street Target
$12.00
(+46.2%)
Revenue Growth (YoY)
-29.7%
Earnings Growth (YoY)
-93.8%
Profit Margin
-1.3%
Valuation Discount vs History
-16.8% cheaper
PE vs Historical
9.0 vs 15.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.8%
(market-implied from PE analysis)
1-Year Target
$7.39
(-10%)
2-Year Target
$6.65
(-19%)
3-Year Target
$5.99
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→16)
$10.35
(+26%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: -4.2%)
$17.63
(+115%)
Base:
(SPY PE: 9.0, Growth: -4.2%)
$7.22
(-12%)
Bear:
(PE: 7.7, Growth: -4.2%)
$6.13
(-25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.0 to 15.6
Stabilization Target:
$14.20
(+72.9%)
PE Expansion Potential:
+72.9%
Share & Embed Analysis
Last updated: May 14, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ronald Richard
SELL
21984 shares
2025-12-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
